Video

Dr. Jonasch on HIF-2α inhibitors in renal cell carcinoma

Author(s):

Urology Times staff

Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Daniel Kwon, MD, answers a question during a Zoom video interview
Related Content
Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke
Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
January 29th 2025

Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

Hannah Clarke
WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
January 22nd 2025

Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

Hannah Clarke
"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
December 24th 2024

Quiz: CUA guidelines on specimen and timing considerations with genetic testing

Patrick Campbell
Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
NCCN reaffirms Prolaris’ prognostic value in prostate cancer
December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke
The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
DNA helix | Image Credit: © Siarhei - stock.adobe.com
December 17th 2024

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer

Patrick Campbell
Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.